Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is reporting third quarter financial results on Wednesday 4th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, IONS is expected to report 3Q20 loss of $ 0.09 per share from revenue of $ 182.14 million.
For the full year, analysts anticipate top line of $ 708.95 million, while looking forward to loss of $ 0.51 per share bottom line.
Previous Quarter Performance
Ionis Pharmaceuticals, Inc. revealed loss for the second quarter of $ 0.23 per share, from the revenue of $ 146.00 million. The quarterly revenues declined 10.87 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.27 per share from $ 148.87 million in revenue. The bottom line results beat street analysts by $ 0.04 or 14.81 percent, at the same time, top line results fell short of analysts by $ 2.87 million or 1.93 percent.
Stock Performance
Shares of Ionis Pharmaceuticals, Inc. traded up $ 0.23 or 0.49 percent on Tuesday, reaching $ 47.00 with volume of 647.30 thousand shares. Ionis Pharmaceuticals, Inc. has traded high as $ 47.68 and has cracked $ 46.47 on the downward trend
According to the previous trading day, closing price of $ 47.00, representing a 18.95 % increase from the 52 week low of $ 39.32 and a 29.37 % decrease over the 52 week high of $ 66.22.
The company has a market capital of $ 6.57 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Underweight rating, with $ 50.00 target price.
Conference Call
Ionis Pharmaceuticals, Inc. will be hosting a conference call at 11:30 AM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.ionispharma.com
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
